Performance of the NeoHoP score ≥2 for the diagnosis of any HAI in the NeoHoP validation cohort, the NeoOBS-SA cohort and the NeoOBS-SA-VLBW cohort
| External validation cohort* | External validation cohort: VLBW only† | Internal validation cohort‡ | ||||
| 95% CI | 95% CI | 95% CI | ||||
| n | 573 | 373 | 552 | |||
| Sensitivity (%) | 65.0 | 60.5–69.4 | 66.1 | 60.2–71.3 | 54.2 | 47.3–60.9 |
| Specificity (%) | 91.6 | 84.6–96.1 | 89.7 | 80.8–95.5 | 96.4 | 93.9–98.2 |
| PLR | 7.7 | 4.1–14.5 | 6.4 | 3.3–12.5 | 15.2 | 8.6–26.9 |
| NLR | 0.38 | 0.33–0.44 | 0.38 | 0.32–0.45 | 0.48 | 0.41–0.55 |
| PPV (%) | 97.1 | 94.7–98.4 | 96.1 | 92.6–97.9 | 90.7 | 84.7–94.5 |
| NPV (%) | 37.6 | 34.4–40.8 | 41.2 | 36.8–45.2 | 76.7 | 73.9–79.2 |
| Diagnostic accuracy (%) | 70.0 | 66.1–73.7 | 71.2 | 66.0–75.4 | 79.9 | 76.3–83.2 |
| Youden index | 0.57 | 0.56 | 0.51 | |||
*External validation cohort includes 346 infants with 573 episodes of suspected HAI selected from the NeoOBS-SA study.17
†External validation cohort: VLBW only is a subset of 222 VLBW infants within the NeoOBS-SA cohort (NeoOBS-SA-VLBW).17
‡Internal validation cohort: the NeoHoP study included 406 VLBW infants with 552 episodes of suspected HAI that were used for internal validation of the NeoHoP score.16
HAI, healthcare-associated infection; NeoOBS, Neonatal Sepsis Observational study; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value; VLBW, very low birth weight.